Efficacy and Safety of Tapencarium (RZL-012) in Submental Fat Reduction

Area of Science:

• Aesthetics
• Dermatology
• Pharmacology

Background:

• Tapencarium (RZL-012) is a novel synthetic molecule with cytolytic properties designed for subcutaneous fat reduction.
• Its injectable form targets and reduces localized fat deposits.

Purpose of the Study:

• To evaluate the safety and efficacy of low- and high-dose RZL-012 compared to placebo for submental fat (SMF) reduction.
• To assess the impact of RZL-012 on submental appearance and fat volume.

Main Methods:

• A 3-armed, randomized, double-blind, placebo-controlled phase 2b study involving 151 patients with excess SMF.
• Single treatment session with RZL-012 or placebo, followed by 84 days of monitoring.
• Assessment of SMF using the Clinician Chin Assessment Tool (C-CAT), Subject Chin Assessment Tool (S-CAT), and MRI.

Main Results:

• High-dose RZL-012 showed significantly higher rates of 1- or 2-grade improvement in C-CAT/S-CAT scores compared to placebo (P < .002).
• A significantly greater relative percentage reduction in MRI-measured SMF volume was observed with high-dose RZL-012 versus low-dose or placebo (P < .0001).
• Local injection site reactions were the most frequent adverse events.

Conclusions:

• Single administration of RZL-012 into SMF led to significant improvements in submental appearance, confirmed by clinicians, patients, and MRI.
• The treatment exhibited a favorable safety profile, with no serious adverse events or clinically significant changes in vital signs or laboratory tests.